论文部分内容阅读
目的研究G蛋白耦联受体30(GPR30)在三阴性乳腺癌中的表达及意义。方法收集178例病理诊断为乳腺癌患者的病理标本,进行免疫组化染色,分析GPR30表达情况及其与临床病理指标的关系。结果雌激素受体(ER)(+)患者GPR30表达率61.46%与ER(-)患者表达率60.98%比较,差异无统计学意义(P>0.05);孕激素受体(PR)(+)患者GPR30表达率61.11%与PR(-)患者表达率59.09%比较,差异无统计学意义(P>0.05);GPR30与ER、PR在乳腺癌患者中的表达是相互独立的,作为独立因素存在。三阴性乳腺癌患者GPR30表达率78.26%与ER(+)患者比较,差异具有统计学意义(P<0.05)。结论 GPR30是预测三阴性乳腺癌患者预后的生物学标志物,GPR30在三阴性乳腺癌内分泌治疗中具有重要作用。
Objective To study the expression and significance of G protein coupled receptor 30 (GPR30) in triple negative breast cancer. Methods A total of 178 pathological specimens of breast cancer patients were collected and immunohistochemically stained to analyze the relationship between the expression of GPR30 and clinicopathological parameters. Results The expression of GPR30 in estrogen receptor (ER) (+) patients was 61.46% compared with 60.98% in ER (-) patients, with no significant difference (P> 0.05) The expression of GPR30 in patients with breast cancer was 61.11%, but the difference was not statistically significant (P> 0.05). The expression of GPR30 and ER, PR in breast cancer patients were independent and existed as independent factors . The expression of GPR30 in triple negative breast cancer patients was 78.26% compared with ER (+) patients, the difference was statistically significant (P <0.05). Conclusion GPR30 is a biomarker to predict the prognosis of triple-negative breast cancer patients. GPR30 plays an important role in the endocrine therapy of triple-negative breast cancer.